Please enable JavaScript to continue using this application.

Compare $ENTA vs $ZNTL | Chartloom

Compare

$ENTA vs $ZNTL

Enanta Pharmaceuticals Inc · Zentalis Pharmaceuticals Inc

ENTA

Enanta Pharmaceuticals Inc

ZNTL

Zentalis Pharmaceuticals Inc

Compare $ENTA vs $ZNTL

Comparing Enanta Pharmaceuticals Inc and Zentalis Pharmaceuticals Inc

ENTAEnanta Pharmaceuticals Inc

ZNTLZentalis Pharmaceuticals Inc

ENTAEnanta Pharmaceuticals Inc

Market cap

$364M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

6.51x

Rev growth (TTM)

0.7%

YTD performance

-13.3%

52W performance

10.6%

FCF yield

-10.2%

ZNTLZentalis Pharmaceuticals Inc

Market cap

$188M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

—

YTD performance

92.7%

52W performance

61.0%

FCF yield

-68.2%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

ENTA

ZNTL

Detailed metrics comparison

ENTA

Enanta Pharmaceuticals Inc

ZNTL

Zentalis Pharmaceuticals Inc

Market Cap

ENTA$364M

ZNTL$188M

Enterprise Value

ENTA$456M

ZNTL$163M

Price

ENTA$12.50

ZNTL$2.64

P/E Ratio

ENTAN/A

ZNTLN/A

P/S Ratio

ENTA5.57x

ZNTL0.00x

EV/Sales

ENTA6.99x

ZNTL0.00x

EV/EBITDA

ENTA31.83x

ZNTL0.00x

P/B Ratio

ENTA3.73x

ZNTL1.70x

P/FCF Ratio

ENTAN/A

ZNTLN/A

EV/FCF

ENTA-12.36x

ZNTL-1.27x

PEG Ratio

ENTAN/A

ZNTLN/A

Forward P/E (NTM)

ENTAN/A

ZNTLN/A

Forward P/S (NTM)

ENTA6.51x

ZNTLN/A

Revenue (TTM)

ENTA$65M

ZNTL$0

Revenue Growth (YoY)

ENTA0.7%

ZNTLN/A

Forward Rev Growth

ENTA-7.3%

ZNTL447.5%

Gross Margin (TTM)

ENTA0.0%

ZNTL0.0%

Operating Margin (TTM)

ENTA0.0%

ZNTL0.0%

EBITDA Margin (TTM)

ENTA-82.5%

ZNTL0.0%

Net Margin (TTM)

ENTA-96.9%

ZNTL0.0%

FCF Margin (TTM)

ENTA-56.6%

ZNTLN/A

Net Income (TTM)

ENTA$-63M

ZNTL$-62M

FCF (TTM)

ENTA$-37M

ZNTL$-128M

EPS (TTM)

ENTA-$2.17

ZNTL$0.00

ROE (TTM)

ENTA-6184.0%

ZNTL-5277.0%

ROA (TTM)

ENTA-2070.0%

ZNTL-4055.0%

ROIC (TTM)

ENTA-2677.0%

ZNTL-5277.0%

Cash

ENTA$33M

ZNTL$25M

Debt

ENTA$126M

ZNTL$0

Net Cash/Debt

ENTA$-93M

ZNTL$25M

Current Ratio (TTM)

ENTA3.76x

ZNTL4.82x

Quick Ratio (TTM)

ENTA3.62x

ZNTL4.64x

Debt/Equity (TTM)

ENTA1.25x

ZNTL0.00x

Debt/Assets (TTM)

ENTA0.0%

ZNTL0.0%

Interest Coverage (TTM)

ENTAN/A

ZNTLN/A

Net Debt/EBITDA (TTM)

ENTA0.00x

ZNTL0.00x

Beta

ENTA0.72

ZNTL1.92

52W Performance

ENTA10.6%

ZNTL61.0%

YTD Performance

ENTA-13.3%

ZNTL92.7%

% from 52W High

ENTA-27.1%

ZNTL-62.0%

% from 52W Low

ENTA22.5%

ZNTL117.8%

Asset Turnover (TTM)

ENTA0.21x

ZNTL0.00x

FCF Yield (TTM)

ENTA-10.2%

ZNTL-68.2%

Earnings Yield (TTM)

ENTA-17.4%

ZNTL-32.9%

Dividend Yield (TTM)

ENTAN/A

ZNTLN/A

Rule of 40

ENTA-55.9

ZNTL0.0

EV/GP/RG

ENTAN/A

ZNTLN/A

Ticker research

View ENTA research View ZNTL research

Metric	ENTA Enanta Pharmaceuticals Inc	ZNTL Zentalis Pharmaceuticals Inc
Market & Valuation
Market Cap	$364M	$188M
Enterprise Value	$456M	$163M
Price	$12.50	$2.64
P/E Ratio	N/A	N/A
P/S Ratio	5.57x	0.00x
EV/Sales	6.99x	0.00x
EV/EBITDA	31.83x	0.00x
P/B Ratio	3.73x	1.70x
P/FCF Ratio	N/A	N/A
EV/FCF	-12.36x	-1.27x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	6.51x	N/A
Revenue & Growth
Revenue (TTM)	$65M	$0
Revenue Growth (YoY)	0.7%	N/A
Forward Rev Growth	-7.3%	447.5%
Profitability
Gross Margin (TTM)	0.0%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-82.5%	0.0%
Net Margin (TTM)	-96.9%	0.0%
FCF Margin (TTM)	-56.6%	N/A
Net Income (TTM)	$-63M	$-62M
FCF (TTM)	$-37M	$-128M
EPS (TTM)	-$2.17	$0.00
ROE (TTM)	-6184.0%	-5277.0%
ROA (TTM)	-2070.0%	-4055.0%
ROIC (TTM)	-2677.0%	-5277.0%
Financial Health
Cash	$33M	$25M
Debt	$126M	$0
Net Cash/Debt	$-93M	$25M
Current Ratio (TTM)	3.76x	4.82x
Quick Ratio (TTM)	3.62x	4.64x
Debt/Equity (TTM)	1.25x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.72	1.92
52W Performance	10.6%	61.0%
YTD Performance	-13.3%	92.7%
% from 52W High	-27.1%	-62.0%
% from 52W Low	22.5%	117.8%
Efficiency & Yields
Asset Turnover (TTM)	0.21x	0.00x
FCF Yield (TTM)	-10.2%	-68.2%
Earnings Yield (TTM)	-17.4%	-32.9%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-55.9	0.0
EV/GP/RG	N/A	N/A
Ticker research	View ENTA research	View ZNTL research

Valuation

P/S Ratio

ZNTL

0.00x

ENTA

5.57x

EV/FCF

ENTA

-12.36x

ZNTL

-1.27x

Growth & revenue

Revenue Growth TTM

ENTA

0.7%

Forward Revenue Growth

ZNTL

447.5%

ENTA

-7.3%

Profitability & performance

Gross Margin

ENTA

0.0%

ZNTL

0.0%

ROE

ZNTL

-5277.0%

ENTA

-6184.0%

FCF Yield %

ENTA

-10.2%

ZNTL

-68.2%

52-Week Performance

ZNTL

61.0%

ENTA

10.6%

Detailed metrics comparison

ENTA

Enanta Pharmaceuticals Inc

ZNTL

Zentalis Pharmaceuticals Inc

Market Cap

ENTA$364M

ZNTL$188M

Enterprise Value

ENTA$456M

ZNTL$163M

Price

ENTA$12.50

ZNTL$2.64

P/E Ratio

ENTAN/A

ZNTLN/A

P/S Ratio

ENTA5.57x

ZNTL0.00x

EV/Sales

ENTA6.99x

ZNTL0.00x

EV/EBITDA

ENTA31.83x

ZNTL0.00x

P/B Ratio

ENTA3.73x

ZNTL1.70x

P/FCF Ratio

ENTAN/A

ZNTLN/A

EV/FCF

ENTA-12.36x

ZNTL-1.27x

PEG Ratio

ENTAN/A

ZNTLN/A

Forward P/E (NTM)

ENTAN/A

ZNTLN/A

Forward P/S (NTM)

ENTA6.51x

ZNTLN/A

Revenue (TTM)

ENTA$65M

ZNTL$0

Revenue Growth (YoY)

ENTA0.7%

ZNTLN/A

Forward Rev Growth

ENTA-7.3%

ZNTL447.5%

Gross Margin (TTM)

ENTA0.0%

ZNTL0.0%

Operating Margin (TTM)

ENTA0.0%

ZNTL0.0%

EBITDA Margin (TTM)

ENTA-82.5%

ZNTL0.0%

Net Margin (TTM)

ENTA-96.9%

ZNTL0.0%

FCF Margin (TTM)

ENTA-56.6%

ZNTLN/A

Net Income (TTM)

ENTA$-63M

ZNTL$-62M

FCF (TTM)

ENTA$-37M

ZNTL$-128M

EPS (TTM)

ENTA-$2.17

ZNTL$0.00

ROE (TTM)

ENTA-6184.0%

ZNTL-5277.0%

ROA (TTM)

ENTA-2070.0%

ZNTL-4055.0%

ROIC (TTM)

ENTA-2677.0%

ZNTL-5277.0%

Cash

ENTA$33M

ZNTL$25M

Debt

ENTA$126M

ZNTL$0

Net Cash/Debt

ENTA$-93M

ZNTL$25M

Current Ratio (TTM)

ENTA3.76x

ZNTL4.82x

Quick Ratio (TTM)

ENTA3.62x

ZNTL4.64x

Debt/Equity (TTM)

ENTA1.25x

ZNTL0.00x

Debt/Assets (TTM)

ENTA0.0%

ZNTL0.0%

Interest Coverage (TTM)

ENTAN/A

ZNTLN/A

Net Debt/EBITDA (TTM)

ENTA0.00x

ZNTL0.00x

Beta

ENTA0.72

ZNTL1.92

52W Performance

ENTA10.6%

ZNTL61.0%

YTD Performance

ENTA-13.3%

ZNTL92.7%

% from 52W High

ENTA-27.1%

ZNTL-62.0%

% from 52W Low

ENTA22.5%

ZNTL117.8%

Asset Turnover (TTM)

ENTA0.21x

ZNTL0.00x

FCF Yield (TTM)

ENTA-10.2%

ZNTL-68.2%

Earnings Yield (TTM)

ENTA-17.4%

ZNTL-32.9%

Dividend Yield (TTM)

ENTAN/A

ZNTLN/A

Rule of 40

ENTA-55.9

ZNTL0.0

EV/GP/RG

ENTAN/A

ZNTLN/A

Ticker research

View ENTA research View ZNTL research

Metric	ENTA Enanta Pharmaceuticals Inc	ZNTL Zentalis Pharmaceuticals Inc
Market & Valuation
Market Cap	$364M	$188M
Enterprise Value	$456M	$163M
Price	$12.50	$2.64
P/E Ratio	N/A	N/A
P/S Ratio	5.57x	0.00x
EV/Sales	6.99x	0.00x
EV/EBITDA	31.83x	0.00x
P/B Ratio	3.73x	1.70x
P/FCF Ratio	N/A	N/A
EV/FCF	-12.36x	-1.27x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	6.51x	N/A
Revenue & Growth
Revenue (TTM)	$65M	$0
Revenue Growth (YoY)	0.7%	N/A
Forward Rev Growth	-7.3%	447.5%
Profitability
Gross Margin (TTM)	0.0%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-82.5%	0.0%
Net Margin (TTM)	-96.9%	0.0%
FCF Margin (TTM)	-56.6%	N/A
Net Income (TTM)	$-63M	$-62M
FCF (TTM)	$-37M	$-128M
EPS (TTM)	-$2.17	$0.00
ROE (TTM)	-6184.0%	-5277.0%
ROA (TTM)	-2070.0%	-4055.0%
ROIC (TTM)	-2677.0%	-5277.0%
Financial Health
Cash	$33M	$25M
Debt	$126M	$0
Net Cash/Debt	$-93M	$25M
Current Ratio (TTM)	3.76x	4.82x
Quick Ratio (TTM)	3.62x	4.64x
Debt/Equity (TTM)	1.25x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.72	1.92
52W Performance	10.6%	61.0%
YTD Performance	-13.3%	92.7%
% from 52W High	-27.1%	-62.0%
% from 52W Low	22.5%	117.8%
Efficiency & Yields
Asset Turnover (TTM)	0.21x	0.00x
FCF Yield (TTM)	-10.2%	-68.2%
Earnings Yield (TTM)	-17.4%	-32.9%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-55.9	0.0
EV/GP/RG	N/A	N/A
Ticker research	View ENTA research	View ZNTL research